Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.

Johnson & Johnson is big winner in CVS diabetes formulary changes

Johnson & Johnson is big winner in CVS diabetes formulary changes

CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.

Drugmakers face challenges marketing new heart drugs

Drugmakers face challenges marketing new heart drugs

Experts say this means drugmakers need to find new ways to communicate the value of their products.

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Eli Lilly will discount its insulins to some patients

Eli Lilly will discount its insulins to some patients

Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

PBMs unveil 2017 formularies, retain focus on exclusions

PBMs unveil 2017 formularies, retain focus on exclusions

Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

Five things for pharma marketers to know: Thursday, March 3, 2016

Five things for pharma marketers to know: Thursday, March 3, 2016

Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad

Eli Lilly's diabetes drugs drive sales

Eli Lilly's diabetes drugs drive sales

The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.